Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
ImmunityBio (NASDAQ: IBRX) stock rose 6.82% to $8.77 in premarket trading. This followed the National Comprehensive Cancer Network (NCCN) updating its 2026 bladder cancer treatment guidelines to include the company's immunotherapy ANKTIVA in combination with bacillus Calmette-Guérin (BCG) for a broader patient population. The stock has gained 314.65% year-to-date. The guideline update is based on clinical data and represents an indication not yet included in ANKTIVA's current FDA-approved label.